newsOn December 8, the Guangdong Provincial Health Commission released the fourth batch of designated medical institutions under the Guangdong-Hong Kong-Macao Greater Bay Area "Hong Kong and Macao Drug and Medical Device Access Policy." Guangdong Pharmaceutical University Guangzhou Fosun Chancheng Hospital (Guangzhou Xinshi Hospital) was included in the list, making it the only designated institution selected from Baiyun District in this batch.
Moving forward, leveraging its existing strengths in specialized departments and the International Medical Center, the hospital will further capitalize on the advantages of the "Hong Kong and Macao Drug and Medical Device Access Policy" to provide more convenient cross-border medical services for the public. This initiative will contribute to the deeper integration and collaborative development of medical resources within the Greater Bay Area.
Access to Advanced International Medicines and Medical Devices from Home
The "Hong Kong and Macao Drug and Medical Device Access Policy" is an important medical regulatory innovation granted to the Guangdong-Hong Kong-Macao Greater Bay Area by the state. It establishes a "special channel" for high-quality medicines and medical devices from Hong Kong and Macao to enter medical institutions in the mainland areas of the Greater Bay Area. The policy allows the compliant use of drugs and medical devices that are already marketed in Hong Kong and Macao, clinically urgent, and technologically advanced in designated medical institutions. This initiative aims to better meet the pressing demand for advanced overseas medicines and medical devices among residents of the Greater Bay Area.
Tan Minghua, Vice President of Fosun Health, Vice President of Fosun Health Greater Bay Area General Hospital, and President of Guangdong Pharmaceutical University Guangzhou Fosun Chancheng Hospital, stated that with the formal implementation of the "Hong Kong and Macao Drug and Medical Device Access Policy," the hospital plans to promote the application and introduction of relevant medicines and medical devices from Hong Kong and Macao in key specialized fields such as neurology, oncology, and chronic disease management. The goal is to further meet the diagnostic and treatment needs of different patient groups and deliver tangible benefits to patients in the Greater Bay Area.
Following this approval, the hospital has promptly launched a dedicated working mechanism. It will strictly adhere to policy and medical ethics requirements, focusing on the urgent clinical needs of patients to systematically advance the application, introduction, and clinical use of cutting-edge medicines and medical devices from Hong Kong and Macao. Additionally, the hospital will optimize internal processes, support "green channels," expedite patient access, and effectively safeguard public health and well-being.
Deepening Cooperation to Comprehensively Benefit the Public with Convenient Healthcare
Since joining Fosun Health, the hospital has consistently driven innovation and transformation, with a focus on developing specialized departments such as minimally invasive surgery, oncology diagnosis and treatment, and the brain science center. Among these, the oncology center treated over 17,000 patients in 2024, demonstrating steadily enhanced diagnostic and treatment capabilities. Concurrently, the hospital has actively integrated into the development initiatives of the Belt and Road Initiative and the Guangdong-Hong Kong-Macao Greater Bay Area by establishing an international medical center, which has already served patients from countries such as Mongolia, Bangladesh, Indonesia, South Korea, Malaysia, and Vietnam within six months, showcasing its emerging influence in international healthcare.
Under the strategic opportunity of national efforts to promote medical integration in the Greater Bay Area, as a key member of Fosun Health’s Greater Bay Area General Hospital, the hospital has maintained an open approach. It has successively signed strategic cooperation agreements with leading institutions such as Hong Kong’s Gleneagles Hospital and Hong Kong Adventist Hospital, deepening collaboration in areas such as joint specialty development, referral of complex cases, and internationally standardized diagnosis and treatment. These efforts continue to empower the high-quality development of the Greater Bay Area's healthcare system.
Furthermore, the hospital has pioneered the "in-hospital elderly care" model by establishing the Baiyun District Xinshi Street Comprehensive Elderly Care Service Center (Yikang Center), which integrates medical and elderly care resources to provide convenient and professional healthcare services for seniors. This model effectively addresses the multi-level care needs of elderly individuals, especially those who are frail, have limited mobility, or are in recovery, and offers a replicable example for integrated medical and elderly care practices in the Greater Bay Area.
Looking ahead, as the integration process in the Greater Bay Area accelerates, the demand for medical treatment, rehabilitation, and residential care among Hong Kong and Macao residents in Guangdong will further expand. The hospital will continue to leverage the advantages of the "Hong Kong and Macao Drug and Medical Device Access Policy," drawing on its solid expertise in specialized treatments, international healthcare, and the integration of medical and elderly care. It will actively align with international service standards to contribute to the integration and collaborative development of medical and elderly care resources in the Guangdong-Hong Kong-Macao Greater Bay Area.